TP53 mutations continue to be a significant area of research focus in the field of cancer. Over the past four decades, extensive studies have shed light on the critical role of TP53 in cancer development and treatment response. The high frequency of TP53 alterations in human cancers underscores the importance of understanding how these mutations interact with genetic and environmental factors to shape disease outcomes.
This comprehensive review, published in the Journal of Internal Medicine, highlights the evolving landscape of TP53 research and its implications for cancer management. In chronic lymphocytic leukemia (CLL), TP53 mutations have emerged as a key prognostic marker, influencing treatment strategies and clinical outcomes. The integration of novel targeted agents has revolutionized the therapeutic approach for CLL patients, offering new possibilities for improved responses and outcomes.
Read more from ajmc.com